Participating in #clinicaltrials plays a key role in driving the development of treatment options for patients. We're currently enrolling participants for several studies for neurodegenerative and rare peripheral amyloid diseases, including #AlzheimersDisease and AL #amyloidosis. For additional information, visit: bit.ly/3YBZygv
About us
Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases. At Prothena, our success is driven by our people. We are dedicated to attracting individuals who share our vision to improve human health by putting patients first. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, while enjoying the journey. Our values connect us – you will see and feel them come to life in all we do – together.
- Website
-
http://www.prothena.com
External link for Prothena Corporation
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Dublin, 2
- Type
- Public Company
- Founded
- 2012
Locations
-
Primary
77 Sir John Rogerson's Quay, Block C
Grand Canal Docklands
Dublin, 2 D02 T804, IE
-
331 Oyster Pt. Boulevard
South San Francisco, CA 94080, US
Employees at Prothena Corporation
Updates
-
We’re wrapping up a productive week at #AAIC24 where we participated in many collaborative discussions with the #Alzheimers community. Thank you, Alzheimer's Association® for hosting such an insightful event as we continue to strive towards advancing treatment options for patients.
-
-
At Prothena, our team is fueled by a deep scientific expertise built over decades of research and experience. Meet Chief Regulatory Officer Carol Karp, and learn more about the impact our regulatory team has in our shared mission to deliver innovative therapies for patients: https://bit.ly/4fuisf2
-
-
Collaboration plays a critical role in shaping the future of #Alzheimers disease treatment options, improving the lives of patients and their families. SVP and Head of Clinical Development, Chad Swanson, PhD shares his excitement to be at #AAIC24, where research and collaboration pave the way for the breakthrough of new treatment options.
-
We’re excited to be in Philadelphia for #AAIC24! We asked our Chief Medical Officer, Hideki Garren, to highlight key insights from the Alzheimer's Association® International Conference.
-
-
Each year, more patients are facing the challenges of a new #Alzheimers diagnosis. As we get ready for #AAIC24 this weekend, it’s important that we continue to shed a light on the prevalence of #AlzheimersDisease, which drives our commitment to advance research, promote awareness, and develop solutions.
This content isn’t available here
Access this content and more in the LinkedIn app
-
We’re committed to making a meaningful difference and advancing treatment options for patients living with #Alzheimers disease. This weekend, we look forward to connecting with researchers and clinicians while delving into the latest advancements in #AlzheimersDisease at Alzheimer's Association®'s International Conference. Learn more and register here: https://bit.ly/3LxOnO7 #AAIC24
-
-
Participation in the AFFIRM-AL study will help us understand whether an investigational medication is effective for adults newly diagnosed with advanced AL #Amyloidosis. Learn more about participating: https://bit.ly/4cXd2YA
-
-
#Alzheimers disease affects nearly 55 million people around the world. At Prothena, we are dedicated to addressing the pressing demand for therapies that slow the progression of, and ultimately prevent the disease. Learn more about our pipeline of Alzheimer’s and other neurodegenerative disease candidates: https://bit.ly/3xQOtxa
-
-
Recognizing the early signs of AL #amyloidosis is crucial, leading to earlier diagnosis and improved treatment outcomes for patients. At Prothena, we’re committed to developing novel and transformative medicines to create a better future for people in critical need. Learn more: https://bit.ly/45sSPGQ
-